RxDoctor Payments Data

Sara Greenhill, MD

Pulmonary Disease · Elk Grove Village, ILNPI 1427016948

Payments from drug & device makers

$16,591in general payments, 2019–2025

Across 289 payments — averaging $57.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$10K
  • GE HealthCare$943
  • Boehringer Ingelheim$777
  • Cook Incorporated$750
  • GSK$677
  • AstraZeneca$464
  • plus $3K from 25 others

What the payments were for

  • Consulting fees$9436%
  • Speaking & faculty fees$7505%
  • Travel & lodging$1,84311%
  • Food & beverage$6,15637%
  • Education$6,50039%
  • Gifts$3992%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,591 in reported general payments places this provider in the 80th percentile of 539 pulmonary disease providers in Illinois.

See all pulmonary disease providers in Illinois

Medicare billing

Part B allowed, 2024
$197,090
Medicare patients
332
Services billed
1,353

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter128$118,291
Stiolto RespimatTiotropium Br/Olodaterol Hcl22$19,441
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr28$15,742
Spiriva RespimatTiotropium Bromide13$14,906
Albuterol Sulfate HfaAlbuterol Sulfate28$735
Azelastine Hcl13$504
Prednisone72$458
Pantoprazole Sodium11$236
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim31$118
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav17$110
Levofloxacin12$59

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta$677$134,033156 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat$777$34,34835 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 539 pulmonary disease providers in Illinois.

Other pulmonary disease in Elk Grove Village

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →